CDK7 targeting in cancer- A review on current trends. Keywords-CDK7,CDK7 inhibitors, cancer

Keywords

Abstract

References

1. [1]Gong.Y, Li.H, CDK7 in breast cancer: mechanisms of action and therapeutic potential, Cell Communication and Signaling, 2024, 22 (226), https://doi.org/10.1186/s12964-024-01577-y. Cristina Guarducci, et.al., Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer, Clin Cancer Res ,2024, 30 (9), 1889–1905. Zeng.S, et.al., CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer, Journal of Experimental & Clinical Cancer Research, 2022, 41, 241, 1-18, https://doi.org/10.1186/s13046-022-02443-w. Yao.Y, et.al., CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma, Blood,2023, 141 (23): 2841–2852. Bao.XJ , et.al., Clinical data analysis of cdks expression and prognosis in breast cancer, WCRJ, 2023, 10: e2475,1-15. Park H, et.al., Abstract LB168: A selective, potent, and orally bioavailable CDK7 inhibitor demonstrates superior anti-cancer activity in colorectal cancer models, Cancer Res., 2024. 84, (7_Supplement): LB168. https://doi.org/10.1158/1538-7445.AM2024-LB168. Zhang.H, et.al., Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors, ACS Med Chem Lett., 2024, 15(8):1213–1220. Eskandrani.R et.al., Targeting Transcriptional CDKs 7, 8, and 9 with Anilinopyrimidine Derivatives as Anticancer Agents: Design,Synthesis, Biological Evaluation and In Silico Studies, . Molecules 2023, 28, 2-24. .Sava.GP et.al, CDK7 inhibitors as anticancer drugs, Cancer and Metastasis Reviews, 2020, 39:805–823. Olson.CM, et.al., Development of a Selective CDK7 Covalent Inhibitor reveals predominant cell-cycle phenotype, Cell Chemical Biology, 2019, 26, 792–803. Aga.Y et.al., Novel Oral Derivative UD-017, a Highly Selective CDK7 Simone.M,et.al., Variolin B and its derivate deoxy-variolin B: New marine natural compounds with cyclin-dependent kinase inhibitor activity, European Journal of Cancer 2005,41, 2366–2377. Yuying Li,et.al., Flavonoids from tartary buckwheat induce G2/M cell cycle arrest and apoptosis in human hepatoma HepG2 cells, Acta Biochim Biophys Sin, 2014, 46, 460–470. Yang.Y,et.al., Oroxylin A induces G2/M phase cell-cycle arrest viainhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells, JPP 2008, 60, 1459–1463. Li.Y, et.al., Flavonoids from tartary buckwheat induce G2/M cell cycle arrest and apoptosis in human hepatoma HepG2 cells, Acta Biochimica et Biophysica Sinica, 2014, 46(6), 460—470.

Authors (2)